Navigation Links
Oncothyreon announces issuance of patent for PX-867
Date:3/20/2008

have the potential to improve the lives and outcomes of cancer patients. For more information, visit http://www.oncothyreon.com.

Forward Looking Statements

In order to provide Oncothyreon's investors with an understanding of its current intentions and future prospects, this release contains statements that are forward looking, including statements related to filing an IND for PX-866, future clinical development plans for PX-866, and plans to seek a collaboration partner for PX-867. These forward-looking statements represent Oncothyreon's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to Oncothyreon's business and the general economic environment. Many of these risks and uncertainties are beyond Oncothyreon's control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, the safety and efficacy of PX-866 and PX-867, and the likelihood of achieving a collaboration agreement for PX-867. There can be no guarantee that the results of preclinical studies will be predictive of either safety or efficacy in future clinical trials. These and other risks and uncertainties are described in the reports and other documents filed by Oncothyreon Inc. with the SEC and/or Canadian regulatory authorities.

Although Oncothyreon believes that any forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncothyreon to present at upcoming investment conferences
2. Oncothyreon reports full year and fourth quarter 2007 financial results
3. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
4. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
5. Oncothyreon launches new corporate website
6. Oncothyreon to present at BIO CEO & Investor Conference
7. Oncothyreon highlights corporate and clinical objectives for 2008
8. Biomira announces plan to change name to Oncothyreon
9. 3SBio Inc. Announces Promotion of David Chen as Chief Operating Officer
10. Society for Biomolecular Sciences Announces 2008 Conference Speaker Line-up
11. BioMS Medical Announces 2007 Year End Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Louis, Missouri (PRWEB) December 23, 2014 GMO ... biotechnology company, Syngenta, are in the process of being consolidated ... case is In Re: Syngenta AG MIR 162 Corn Litigation, ... District of Kansas. , Management of the Syngenta GMO corn ...
(Date:12/24/2014)... SoundConnect’s 2015 next ... edge communication technology, provide continued education and inform ... series demonstrates online communication features and benefits; empowering ... most innovative and powerful tools. , According to ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 According to Ross ... Island Affiliate of ITRA Global, the national office market continues ... recovery. This is evidenced by the third quarter’s surprising ... market. Low energy costs have held inflation down and ...
(Date:12/24/2014)... Nashville Fertility Center announced that Dr. ... Society for Reproductive Medicine (ASRM), a leading professional organization committed ... his new role as treasurer, Dr. Hill also fills a ... in furthering the mission of ASRM. , Dr. Hill ...
Breaking Biology Technology:Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3
... - Biomira Inc. (Nasdaq: BIOM ),(TSX: BRA) ... a randomized Phase II trial of the Stimuvax(R) ... results suggest that Stimuvax,combined with best supportive care ... stage IIIB NSCLC who had either responded or ...
... Calif., Sept. 5 Hyperion,Therapeutics, a biopharmaceutical company ... hepatology therapies for the,treatment of Urea Cycle Disorders ... million Series B financing. Leading the round was,Sofinnova ... and,NEA, all of Menlo Park, CA. WRF Capital ...
... 5 Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) announced ... Bear Stearns 20th Annual Healthcare Conference on September,11, 2007 ... at the Grand,Hyatt Hotel in New York City. Jack ... provide a corporate overview of the,company and its clinical ...
Cached Biology Technology:Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer 2Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer 3Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer 4Hyperion Therapeutics Secures $40 Million In Series B Round 2Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference 3
(Date:12/22/2014)... 2014 Holiday Season may be the brightest ever for ... the long anticipated floodgates for consumer biometrics may finally ... phones, tablets, and wearable mobile devices that incorporate biometrics ... with nearly 4.8 billion biometric devices by 2020.   ...
(Date:12/19/2014)... 18, 2014   LaunchKey , the first decentralized mobile ... Internet of Things era, today announced the close of ... was led by Metamorphic Ventures with participation from ENIAC ... and others.  LaunchKey has raised $4 million to date, ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... starfish to carry out one of the most remarkable forms ... by first extending its stomach out of its mouth and ... and clams. The prey tissue is partially digested externally before ... digestive glands. , The researchers at Queen Mary, University of ...
... article published in this month,s issue of Pediatrics ... Medicine (BUSM) stress the importance of physicians recognizing that ... to make accurate health assessments for both mother and ... guidelines set a standardized risk assessment of herbal supplement ...
... will present the Society,s highest honor, the 2013 Wallace ... Professor Sir David Weatherall, MD, of the University of ... combining seminal discoveries, visionary translational research leadership, and a ... improve clinical care for thousands throughout the developing world. ...
Cached Biology News:Scientists uncover secrets of starfish's bizarre feeding mechanism 2Study finds physicians need to better recognize use of herbal supplements while breastfeeding 2Professor Sir David Weatherall, M.D., recieves 2013 Wallace H. Coulter Award 2Professor Sir David Weatherall, M.D., recieves 2013 Wallace H. Coulter Award 3Professor Sir David Weatherall, M.D., recieves 2013 Wallace H. Coulter Award 4
Mouse Iduronate 2-Sulfatase Affinity Purified Polyclonal Ab Keywords: Sulfatases, Iduronate 2-Sulfatase, Mucopolysaccharidosis, Hunter Syndrome, Glycobiology Protein Family: Proteoglycan Regu...
Request Info...
Mouse Limitin MAb (Clone 183727)...
Normal human serum collected off the clot from healthy normal humans. Each donor unit is negative for anti-HIV 1&2, HIV-Ag, HCV, and HBsAg by FDA required tests...
Biology Products: